SELECT | Jotup

Nearly Two-Thirds of Homeowners See Home Improvement Projects as an Alternative to Buying a New Home, According to CRAFTSMAN® Home Field Advantage Survey

Retrieved on:

Dienstag, Dezember 5, 2023

"Whether it's a kitchen revamp, built-in closets, or building a backyard oasis, CRAFTSMAN has the tools homeowners need to transform their current home into their dream home."

Key Points:

"Whether it's a kitchen revamp, built-in closets, or building a backyard oasis, CRAFTSMAN has the tools homeowners need to transform their current home into their dream home."
The most popular areas for improvement: The most commonly considered projects include painting (51%), bathroom improvements (44%) and kitchen improvements (41%).
The tools homeowners want to use: When it comes to sourcing tools, 64% of homeowners surveyed show a tendency to buy the necessary tools rather than borrow.
The margin of error for the overall sample is +/- 2 percentage points with a confidence level of 95 percent.

TOS Past Presidents Comment on SELECT Study Results

Retrieved on:

Dienstag, November 14, 2023

ROCKVILLE, Md., Nov. 14, 2023 /PRNewswire/ -- New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society (TOS) and published in The New England Journal of Medicine.

Key Points:

Apovian is professor at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, Boston, Mass.
I felt that the audience had confidence in the results because of the precision with which the study was executed.
To view a copy of the study titled "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," visit The New England Journal of Medicine website.
Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity.

Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions

Retrieved on:

Dienstag, November 7, 2023

Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.

Key Points:

Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.
Late-breaking scientific abstracts will be posted online at the exact date and time the embargo lifts.
Data from the SELECT trial will be presented live during a late-breaking science session at 8:30-9:15 AM EST on November 11.
As expected, there is significant risk with drug development and no guarantee that future studies will reflect similar results as presented at AHA.

Refreshed 2024 Rogue Is First Nissan to Come With Google Built-In

Retrieved on:

Montag, Oktober 16, 2023

The 2024 Nissan Rogue receives a bold exterior refresh and significant available technology upgrades to make every trip more convenient and better connected.

Key Points:

The 2024 Nissan Rogue receives a bold exterior refresh and significant available technology upgrades to make every trip more convenient and better connected.
The 2024 Nissan Rogue receives a bold exterior refresh and significant available technology upgrades to make every trip more convenient and better connected.
The 2024 Nissan Rogue goes on sale at U.S. dealerships in early 2024 with pricing to be announced at a later date.
(Photo: Business Wire)
The 2024 Nissan Rogue goes on sale at U.S. dealerships in early 2024 with pricing to be announced at a later date.

DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease

Retrieved on:

Donnerstag, Oktober 12, 2023

The following statement can be attributed to Dr. Jeff Giullian, chief medical officer for DaVita Inc.

Key Points:

The following statement can be attributed to Dr. Jeff Giullian, chief medical officer for DaVita Inc.
"We've been closely monitoring the developments related to GLP-1s, and are excited about the potential benefits this class of drugs could have on society and patients with kidney disease.
We will continue monitoring closely as further evidence becomes available to identify the potential benefit of GLP-1s to those afflicted with kidney disease.
In the meantime, DaVita remains focused on providing exceptional patient care and advancing the practice of kidney care."
The trial sought to demonstrate benefits for the composite endpoint comprised of five separate endpoints: death from kidney disease; death from cardiovascular disease; sustained reduction in GFR by at least 50%; progression to stage 5 CKD; and initiation of chronic kidney replacement therapy.

UNITEDMASTERS PARTNERS WITH SYMPHONYOS AND GROOVER TO PROVIDE INDEPENDENT ARTISTS WITH TOOLS TO FUEL THEIR CAREERS

Retrieved on:

Dienstag, September 26, 2023

Creativity, Music, SELECT, Strategic partnership, Love, Social media, Marketing, UnitedMasters, Northeast Groovers

NEW YORK, Sept. 26, 2023 /PRNewswire/ -- UnitedMasters, the leading software and services platform for independent artists, has significantly expanded its mission to empower artists at every stage of their music careers by unveiling two exclusive partnerships with AI-powered marketing platform SymphonyOS and the music promotion platform Groover.

Key Points:

SymphonyOS and Groover will offer UnitedMasters artists exclusive access to music marketing and promotional tools designed to boost exposure.
The partnerships with SymphonyOS and Groover are part of unveiling a powerful set of artist tools designed to enhance fan connection and deliver breakthrough exposure to artists.
UnitedMasters recognizes that one of the biggest challenges independent artists face is gaining exposure that truly matters.
UnitedMasters continues to be at the forefront of revolutionizing the music industry, empowering independent artists to reach their full potential.

Bring on the Project List: CRAFTSMAN® Adds New Tools to its Cordless V20* Lineup

Retrieved on:

Mittwoch, September 20, 2023

Lithium, Lowe's, Maxima and minima, PSI, Stanley Black & Decker, Lowe, Ace Hardware, SELECT, SKU, V20, Workload, Grease gun, Hand, Telescopic sight, Online shopping

The latest CRAFTSMAN V20* offerings include a misting fan, right angle drill, high pressure inflator, grease gun, caulk gun and 1/4-In.

Key Points:

The latest CRAFTSMAN V20* offerings include a misting fan, right angle drill, high pressure inflator, grease gun, caulk gun and 1/4-In.
"CRAFTSMAN's cordless V20* tools are designed to tackle projects big or small, from the garage to the yard, and everywhere in between," said Tabata Gomez, Chief Marketing Officer of Tools & Outdoor, Stanley Black & Decker.
"Our versatile and innovative product line-up gives everyone the confidence, that with CRAFTSMAN in their hand, there's nothing they can't do."
The new CRAFTSMAN V20* products offer user-friendly features and cordless freedom, ideal for completing a wide range of projects including:
V20* Cordless Misting Fan ( CMCE003C1 ) – The cordless misting fan offers effortless cooling in a lightweight and portable design.

NextMed Highlights Revolutionary Findings: Wegovy's Potential in Reducing Cardiovascular Risks by 20%

Retrieved on:

Donnerstag, August 10, 2023

Given the global prevalence of obesity and its associated health risks, the demand for comprehensive and effective treatments has never been higher.

Key Points:

Given the global prevalence of obesity and its associated health risks, the demand for comprehensive and effective treatments has never been higher.
Recognized for its weight loss properties, recent findings indicate its potential to notably reduce the risk of critical cardiovascular events.
The notable improvement in cardiovascular health, even for those without diabetes, indicates that Wegovy's benefits extend beyond just weight reduction, offering deeper metabolic and cardiovascular enhancements.
With the emerging data on Wegovy, NextMed foresees increased interest in consultations related to weight management and cardiovascular health.

ChainSys Corporation Achieves SELECT Partner Status with Snowflake

Retrieved on:

Mittwoch, Juli 26, 2023

ROCKLIN, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- ChainSys Corporation, a leading global data management platform provider, announced today that it has achieved SELECT LEVEL tier partner status from Snowflake, the Data Cloud company.

Key Points:

ROCKLIN, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- ChainSys Corporation, a leading global data management platform provider, announced today that it has achieved SELECT LEVEL tier partner status from Snowflake, the Data Cloud company.
ChainSys offers over 80% acceleration to data migration journeys to Snowflake Data Cloud from Hadoop, SQL, Oracle, and other legacy data warehouse solutions.
ChainSys and Snowflake Use Case:
ChainSys and Snowflake offer a joint solution for data migration from various ERP systems (SAP), Oracle, Microsoft, etc.)
Customers Leveraging the Smart Data Platform:
ChainSys is excited to become a Snowflake partner and offer customers a trusted data partner for all their data migration and data quality needs.

Cloud Database and DBaaS Market worth $57.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Mittwoch, Juli 12, 2023

North America is expected to have the largest market size in the Cloud Database and DBaaS Market, and the trend is expected to continue till 2028.

Key Points:

North America is expected to have the largest market size in the Cloud Database and DBaaS Market, and the trend is expected to continue till 2028.
During the forecast period, it is anticipated that the market for cloud databases and DBaaS in North America will expand significantly.
Cloud Database and DBaaS Market Advantages:
Because cloud databases and DBaaS solutions offer seamless scalability, organisations may easily increase or decrease their database resources in response to demand.
Cloud databases effortlessly connect with other cloud services and technologies, including serverless computing, data lakes, analytics platforms, and machine learning tools.